Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
OmniAb Inc. (OABIW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/28/2025: OABIW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -5.56% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/28/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.65 | 52 Weeks Range 0.16 - 0.63 | Updated Date 05/17/2025 |
52 Weeks Range 0.16 - 0.63 | Updated Date 05/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -229.11% | Operating Margin (TTM) -453.64% |
Management Effectiveness
Return on Assets (TTM) -13.18% | Return on Equity (TTM) -21.32% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 92829276 |
Shares Outstanding - | Shares Floating 92829276 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
OmniAb Inc.
Company Overview
History and Background
OmniAb, Inc. (formerly Ligand Sciences 2.0) is a company focusing on the discovery and development of human therapeutic antibodies. It was founded in 2022 following the spin-off of Ligand Pharmaceuticalsu2019 antibody discovery business. The company aims to provide researchers with access to next-generation antibody technologies and facilitate the development of innovative therapies.
Core Business Areas
- Antibody Discovery: This segment focuses on the development and licensing of transgenic animals for antibody discovery. These animals are engineered to produce human antibodies, which can be used to develop new therapies for a variety of diseases.
- Technology Licensing: OmniAb licenses its antibody discovery platforms to pharmaceutical and biotechnology companies, enabling them to generate and screen human antibodies for their own drug development programs.
- Partnerships and Collaborations: OmniAb collaborates with pharmaceutical companies and academic institutions to develop new antibody-based therapies.
Leadership and Structure
Matt Foehr is the President and CEO. The organizational structure includes departments for research and development, licensing, and business development. The Board of Directors oversees the strategic direction of the company.
Top Products and Market Share
Key Offerings
- OmniAb Platform: The OmniAb platform is a suite of transgenic animals that produce fully human antibodies. The platform is licensed to pharmaceutical and biotechnology companies for antibody discovery. Market share data is not readily available. Competitors include companies with similar antibody discovery platforms such as Harbour BioMed and Ablexis.
- License Agreements: OmniAb generates revenue through license agreements with pharmaceutical and biotechnology companies. Exact revenue figures from specific license agreements are typically not publicly disclosed. Competitors include companies with similar antibody discovery technology platforms.
Market Dynamics
Industry Overview
The antibody therapeutics market is a large and growing market, driven by the increasing prevalence of chronic diseases and the development of new antibody-based therapies. The market is highly competitive, with a number of large pharmaceutical companies and smaller biotechnology companies developing antibody therapeutics.
Positioning
OmniAb is positioned as a technology provider for antibody discovery. Its competitive advantages include its portfolio of transgenic animals and its expertise in antibody engineering.
Total Addressable Market (TAM)
The total addressable market for antibody discovery technologies is estimated to be in the billions of dollars. OmniAb is positioned to capture a significant share of this market through its licensing agreements and partnerships.
Upturn SWOT Analysis
Strengths
- Proprietary OmniAb platform
- Strong intellectual property position
- Experienced management team
- Established partnerships with pharmaceutical companies
Weaknesses
- Reliance on licensing revenue
- Competition from other antibody discovery platforms
- High development costs
- Potential regulatory hurdles
Opportunities
- Expansion of platform capabilities
- Development of new antibody-based therapies
- Entry into new markets
- Acquisition of complementary technologies
Threats
- Competition from established pharmaceutical companies
- Patent infringement lawsuits
- Changes in regulatory landscape
- Economic downturn
Competitors and Market Share
Key Competitors
- HBM Holdings Limited (2142.HK)
- Ablexis, LLC (Private)
- Creative Biolabs (Private)
Competitive Landscape
OmniAbu2019s advantages include its established platform and strategic partnerships. Disadvantages may stem from competition with larger, more established companies.
Major Acquisitions
Ab Initio Biotherapeutics
- Year: 2024
- Acquisition Price (USD millions): 56.5
- Strategic Rationale: Expanded OmniAb's antibody discovery technologies and increased its portfolio of preclinical therapeutic antibody assets.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is tied to the licensing of their OmniAb platform and collaborations. Data not readily available.
Future Projections: Future growth is dependent on continued licensing agreements and the success of partner programs utilizing their technology. Analyst estimates not available.
Recent Initiatives: Focus on expanding licensing agreements and partnering with companies to develop antibody therapeutics. No other initiatives are known at this time.
Summary
OmniAb is a company focused on antibody discovery through its OmniAb platform and related licensing agreements. The company's main strength lies in its proprietary technology, but reliance on licensing revenue and competition pose ongoing challenges. They need to manage risk by improving market access and product portfolio. Recent acquisitions help the company to improve its technical capabilities.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Press releases
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share estimates are approximate and based on available data and industry analysis.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About OmniAb Inc.
Exchange NASDAQ | Headquaters Emeryville, CA, United States | ||
IPO Launch date 2021-09-30 | President, CEO & Director Mr. Matthew W. Foehr | ||
Sector Healthcare | Industry Biotechnology | Full time employees 114 | Website https://www.omniab.com |
Full time employees 114 | Website https://www.omniab.com | ||
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company's animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. The company has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.